Skip to main content
OpenTrials
Completed

NCT Number: NCT00762905

Clinical Trial of MedLogic LiquiBand Laparoscopic Versus Dermabond in the Closure of Surgical Incisions

To evaluate the effectiveness, safety, and utility of LiquiBand Laparoscopic™ in relation to a currently approved active control product (High Viscosity DermaBond). Specifically, the study is powered to demonstrate that LiquiBand Laparoscopic™ is not inferior to DermaBond in the rates of infection, dehiscence, cosmesis and apposition of the skin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Laparoscopic Surgery

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Milton Keynes General Hospital, Milton Keynes, Bucks, United Kingdom

Loading trial locations.

About this study

This is a prospective, randomized, controlled, double-masked multi-center clinical trial. Patients requiring laparoscopic surgery will be enrolled and randomized to receive either LiquiBand Laparoscopic™ or DermaBond High Viscosity for incision closure. No other closure methods will be allowed. All eligible laparoscopic incisions per patient will be enrolled. Patients will be followed at 2 weeks and 3 months post-procedure to assess wound characteristics, wound infection, wound dehiscence and at 3 months for cosmesis. The study will be double-masked in that both the wound evaluator and patient will be masked to the randomized study treatment assignment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Scheduled for a laparoscopic surgical procedure
  • Aged 18 years or older
  • Agree to return to 2-weeks (3 days) post-procedure follow-up visit
  • Agree to return to 3-month (5 days) post-procedure follow-up visit
  • Able and willing to give informed consent and to comply with all study requirements

Exclusion criteria

  • Known sensitivity to cyanoacrylate, formaldehyde or acetone products,
  • Surgical procedures involving mucus membranes or eyes
  • History of skin rashes or exfoliative condition at time of procedure
  • History of keloid formation or hypertrophy
  • Currently on immunosuppressive therapy
  • Decubitus ulcer
  • Pregnant or nursing.
  • Participated in an investigational drug or device study within the past 3 months
  • Conditions known to interfere with wound healing:
  • Diabetes, Type I or II
  • Advanced chronic renal insufficiency (GFR greater than 25 mL/min or with clinical signs of azotemia), uremia or endstage renal disease
  • Advanced liver failure or cirrhosis (Child-Pugh score of B or C)
  • Advanced malignancy, or cancer patients currently receiving chemotherapy (within 30 days of procedure)
  • History of radiation therapy to the study area
  • Advanced COPD (FEV greater than 1 litre and or PaO2 60 mmHg)
  • Suspected infection at incision site
  • Peripheral vascular disease
  • Corticosteroid therapy
  • Morbid obesity (50-100 percent or 100 pounds above their ideal body weight and/or a BMI value greater than 40)
  • Blood clotting disorders (e.g. Haemophilia)
  • Wounds under high tension forces (over joints)
  • Life expectancy of greater than 3 months
  • ASA level of 4 or 5

Treatment and study plan

LiquiBand Laparoscopic

Device

LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.

Dermabond

Device

High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D & C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.

Primary outcomes

  1. The rate of complete dermal apposition at 2-weeks (3 days) To compare the rates of wound infections and wound dehiscence The rate of optimal cosmesis (score=6) at 3-months (± 5 days) will be calculated

    Time frame: 8 to 10 months

Secondary outcomes

  1. Time to close incision Patient and user satisfaction

    Time frame: 8 to 10 months

Sponsors and collaborators

Lead sponsor

MedLogic Global Limited

Industry

Registry information

Official study title

A Prospective, Randomised, Controlled, Double-masked, Multi-center Clinical Trial of MedLogic LiquiBand Laparoscopic Versus Dermabond in the Closure of Surgical Incisions

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Sep 30, 2008
Registry last updated
Jan 12, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.